Patent 11937587 was granted and assigned to Regeneron Pharmaceuticals on March, 2024 by the United States Patent and Trademark Office.
Non-human animals, expressing humanized CD3 proteins are provided. Non-human animals, e.g., rodents, genetically modified to comprise in their genome humanized CD3 proteins are also provided. Additionally, provided are methods and compositions of making such non-human animals, as well as methods of using said non-human animals.